MET and synovial sarcoma: It was reported that the synovial sarcoma Aska-SS cell line expressed an activated ALK variant and showed sensitivity to ALK inhibitors, while another synovial sarcoma cell line Yamato-SS overexpressed MET protein and exhibited sensitivity to the ALK/MET dual inhibitor, crizotinib [49, 50].